Chelsea Therapeutics is on the verge of delivering novel medications that will provide for our patients’ unmet needs. We are committed to providing new medications that will improve patients’ quality of life.
Chelsea Therapeutics specializes in the acquisition and development of innovative products and technologies that address important unmet medical needs or offer alternatives to current methods of treatment.
Founded in 2004 around its library of unique non-metabolized antifolate technology, Chelsea has since transitioned into a public company and further expanded its product development portfolio with early and late stage product candidates that leverage the company’s development expertise and accelerate the company’s drug commercialization efforts.
Chelsea is pursuing an orphan
drug strategy for the development of droxidopa,
an orally active synthetic precursor of norepinephrine, for the
treatment of symptomatic neurogenic orthostatic hypotension (Neurogenic OH or NOH).* Since acquiring the global development and commercialization rights to droxidopa in 2006 from Dainippon
Sumitomo Pharma Co., Ltd., excluding Japan, Korea, China and Taiwan, Chelsea has conducted multiple clinical trials investigating both safety and efficacy of the drug, including Clinical Study 301, the pivotal proof of efficacy study. In 2011, Chelsea submitted its first New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval to market droxidopa for the treatment of symptomatic Neurogenic OH.*
In addition to droxidopa, Chelsea is developing a portfolio of metabolically
inert antifolate compounds engineered to treat a range of
immunological disorders, including two clinical stage product candidates: CH-1504 and CH-4051. Preclinical and clinical trials are ongoing, investigating the compounds’ potential application in the treatment of rheumatoid arthritis. Antifolate compounds may have further
therapeutic applications for psoriasis,inflammatory bowel disease, uveitis, ankylosing spondylitis, cancer and other immunological disorders.
Chelsea's antifolate program is complemented by its I-3D
portfolio of therapeutics targeting immune-mediated inflammatory
disorders and organ transplantation.
*Droxidopa is an investigational new drug not currently marketed in North America and the European Community. No claims on the safety and efficacy of droxidopa for the treatment of neurogenic orthostatic hypotension are being made, implied, or intended by the resources contained here within.